Israeli AI healthcare startup, MetaSight Diagnostics, emerged from stealth mode and announced a significant partnership with Kahn-Sagol-Maccabi (KSM), the Research and Innovation Center of Maccabi Health Services. The collaboration aims to conduct extensive metabolomics research, utilizing hundreds of thousands of de-identified serum samples and electronic health records (EHRs).
The partnership marks a significant step towards the development of multi-disease liquid biopsies, which could revolutionize early detection and monitoring of various diseases, including cancer, liver, cardiovascular, kidney, and neurological conditions.
MetaSight’s proprietary high-throughput and cost-effective mass spectrometry technology has enabled the creation of the world’s largest serum molecular dataset. While the liquid biopsy market is currently dominated by oncology genomics, MetaSight aims to broaden its scope. The company is developing a unique mass-spectrometry, multi-omics approach to address the lack of accurate, accessible, and affordable diagnostic solutions for a range of other potentially deadly and debilitating conditions.
The metabolomic research conducted by MetaSight will utilize liquid chromatography-mass spectrometry (LC-MS) instruments and consumables from Thermo Fisher Scientific.
This partnership between MetaSight and KSM represents a significant advancement in the field of liquid biopsy diagnostics, potentially paving the way for early detection and monitoring of a wide range of diseases on a global scale.
MetaSight was founded by Tomer Shlomi. They’re a participant of the StarFinder Lab, an innovation platform powered by Roche and aMoon, to incubate AI-powered startups and assist in building their Proof-of-Concepts.